-
Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) jumped $0.71 (11%) to $7.21 on Monday after reporting Phase Ib data for ACH-2684 in 30 patients with HCV genotype 1 infection. Once-daily 100 mg oral ACH-2684 led to a mean …
Published on 5/21/2012
-
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) gained $0.09 (21%) to $0.53 on Monday after reporting top-line data from a Phase IIb trial of bavituximab as a second-line treatment for locally advanced or metastatic non-…
Published on 5/21/2012
-
Johnson & Johnson (NYSE:JNJ) said induction therapy with low- and high-dose Simponi golimumab each met the primary endpoint of a greater proportion of patients achieving a clinical response at week six vs. placebo in …
Published on 5/21/2012
-
A widely used combination treatment for idiopathic pulmonary fibrosis led to significantly greater rates of death, hospitalization, acute exacerbations and serious adverse events compared to placebo in the Phase III …
Published on 5/21/2012
-
Active Biotech AB (SSE:ACTI) and partner Ipsen Group (Euronext:IPN) said oral tasquinimod led to median overall survival of 34.2 months vs. 30.2 months for placebo in a Phase II trial in 206 asymptomatic, metastatic …
Published on 5/18/2012
-
Bavarian Nordic A/S (CSE:BAVA) said ProstVac in combination with Quadramet led to a progression-free survival rate at four months of 29.4% vs. 11.8% for Quadramet alone in a Phase II trial to treat castration-resistant …
Published on 5/18/2012
-
According to a meta-analysis published in The Lancet, lowering LDL-C with statins reduced the risk of major vascular events in all patients, including those at lowest risk for such events. In the paper, researchers from…
Published on 5/18/2012
-
Ramucirumab, a mAb against VEGFR-2 from Eli Lilly and Co. (NYSE:LLY), led to a 34% progression-free survival rate at six months in a Phase II trial in 60 ovarian cancer patients, according to an abstract slated for …
Published on 5/17/2012
-
Array BioPharma Inc. (NASDAQ:ARRY) announced the availability of abstracts slated for presentation at the American Society of Clinical Oncology meeting, including one with detailed data from a Phase II trial of …
Published on 5/17/2012
-
Bristol-Myers Squibb Co. (NYSE:BMY) reported data from three cohorts of patients with advanced or recurrent malignancies in a Phase Ib trial of BMS-936558, a mAb against PD-1 receptor (PDCD1; PD-1; CD279). The trial …
Published on 5/17/2012
-
Neoadjuvant therapy with Zytiga abiraterone plus leuprolide and prednisone led to a pathological complete response in 3 of 29 men with localized high-risk prostate cancer who received the combination for 24 weeks prior …
Published on 5/17/2012
-
Several Pfizer Inc. (NYSE:PFE) abstracts were released Thursday ahead of the American Society of Clinical Oncology meeting, including one with additional data from a trial that supported accelerated approval of Xalkori …
Published on 5/17/2012
-
Amgen Inc. (NASDAQ:AMGN) said rilotumumab plus chemotherapy significantly improved median overall survival vs. chemotherapy alone in patients with gastric tumors exhibiting high c-MET expression (11.1 vs. 5.7 months, p=…
Published on 5/16/2012
-
Some genetic variants that increase plasma HDL-C do not also reduce the risk of myocardial infarction, according to a study published in The Lancet. In the paper, researchers from the Massachusetts General Hospital and …
Published on 5/16/2012
-
Pfizer Inc. (NYSE:PFE) said IV Torisel temsirolimus missed the primary endpoint of progression-free survival (PFS) vs. oral Nexavar sorafenib in the Phase III INTORSECT trial to treat advanced renal cell carcinoma in …
Published on 5/15/2012
-
H. Lundbeck A/S (CSE:LUN) gained DKK9.60 to DKK118.60 on Monday after Lu AA21004 -- a serotonin modulator and stimulator -- significantly improved depression rating scores vs. placebo in three identical Phase III trials…
Published on 5/14/2012
-
Mologen AG (Xetra:MGN) jumped EUR 1.90 (20%) to EUR 11.40 on Monday after twice-weekly MGN1703 as maintenance therapy met the primary endpoint of median progression-free survival vs. placebo in the Phase II IMPACT trial…
Published on 5/14/2012
-
Paion AG (Xetra:PA8) said all 75 evaluable patients undergoing surgery who received IV remimazolam for the induction of general anesthesia achieved loss of consciousness and underwent successful intubation in a Phase II…
Published on 5/14/2012
-
Ventrus Biosciences Inc. (NASDAQ:VTUS) gained $1.62 (15%) to $12.58 on Monday after the company's topical formulation of diltiazem hydrochloride (VEN 307) met the primary endpoint in a Phase III trial to treat anal …
Published on 5/14/2012
-
Cytochroma Inc. (Markham, Ontario) said CTAP101 significantly reduced mean intact parathyroid hormone (PTH) levels from baseline to week six vs. placebo in a Phase IIb trial to treat vitamin D insufficiency in patients …
Published on 5/11/2012
-
Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) said it discontinued development of SUN11031, a human ghrelin that was in Phase III testing in Japan to treat anorexia nervosa. The pharma said that the "expected goal …
Published on 5/11/2012
-
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said vedolizumab met two of three co-primary endpoints in the Phase III GEMINI II trial to treat moderate to severe Crohn's disease (CD). The humanized mAb against integrin …
Published on 5/11/2012
-
Eight months after an FDA panel recommended clarifying the duration of use in labels of bisphosphonates for osteoporosis, the agency said further investigation on the benefit-risk profile is still needed to determine …
Published on 5/10/2012
-
PolyMedix Inc. (OTCBB:PYMX) discontinued development of PMX-60056 and stopped enrollment in a pair of clinical trials after reports of reductions in blood pressure associated with the compound. PMX-60056 was in a Phase …
Published on 5/10/2012
-
Seattle Genetics Inc. (NASDAQ:SGEN) said Adcetris brentuximab vedotin produced 12 partial responses and three cases of stable disease in 16 evaluable patients with relapsed CD30-positive cutaneous T cell lymphoma in an …
Published on 5/10/2012